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Abstract
Bipolar disorder is a mental disorder associated with abnormal inositol levels. Preliminary studies
show omega-3 fatty acids alter intracellular inositol levels; however, the cellular mechanism behind
this process is unknown. Therefore, the focus of this study is to determine the effects of the omega3 fatty acid docosahexaenoic acid (DHA) on the expression of INM1 which encodes inositol
monophosphatase. Using yeast as our model system, cells were grown in varying concentrations
DHA and the expression on INM1 was determined by RT-qPCR. The results show INM1
expression increased with increasing concentrations of DHA; thus, the effects of DHA on inositol
levels may be exerted via its impact on INM1 expression.

Introduction
Bipolar disorder is a psychiatric illness that includes episodes of mania and depression. This
illness is defined in two categories: bipolar I disorder (BP-1) and bipolar II disorder (BP-2). BP-1
includes symptoms of increased manic episodes, while BP- 2 includes depressive stages with a less
intense form of mania called hypomania (Vieta et al. 1997). Current well used treatments for bipolar
disorder include lithium and valproate (VPA). These drugs both decrease the intensity and frequency
of the manic stage, with lithium being slightly more effective compared to valproate (Freeman et al.
1992). However, both treatments come with negative side effects.
A potential alternative treatment for bipolar disorder is omega-3 fatty acids (Shakeri et al.
2016). They have been studied extensively because omega-3 fatty acids are recognized for their
health benefits (Simopoulos 1991). In using them as alternative treatments for bipolar disorder, side
effects that could threaten the health and safety of patients are avoided.
Silverstone and colleagues (2005) discovered that patients suffering from bipolar disorder
had abnormal intracellular inositol levels. Inositol is a chemical compound that plays an important
role in secondary messenger signaling in the brain. Preliminary work in Dr. Marlene Murray’s lab
indicate that intracellular inositol levels are influences by omega-3 fatty acids (M. Murray, personal
communication). To study the mechanism by which omega-3 fatty acids influence inositol levels,
yeast cells were used as a model system for deciphering this mechanism. The yeast gene INM1,
which encodes inositol monophosphatase, is essential in the biosynthesis of inositol. Although
omega-3 fatty acids have been shown to influence the amounts of inositol produced, the
mechanisms behind how omega-3 fatty acids work on a cellular level in this process have not been
confirmed (Murray and Greenberg, 2000). Therefore, the focus of my study was determining the
effects of the omega-3 fatty acid docosahexaenoic acid (DHA) on the expression of the INM1 gene,
a key component in inositol biosynthesis.

Background
Lithium and VPA are known to have various negative side effects, including nausea, tremors,
and skin diseases such as psoriasis when treating bipolar disorder (Deandrea 1982). They are also
primarily used to treat symptoms of mania since they are relatively ineffective in treating the
depressive symptoms in bipolar disorder. As a result, omega-3 fatty acids are studied as an
alternative treatment because they do not cause negative side effects and are likely to decrease
symptoms of depression in bipolar disorder (Shakeri et al. 2016).
Stoll et al. (1999) showed in their study that omega-3 fatty acid ethyl esters (derivatives of
omega-3) inhibit signal transduction pathways in neurons. They found that using these derivatives
stabilized mood swings in bipolar disorder patients by stopping excessive cell signaling. This study
concluded that patients treated with omega-3 fatty acids showed reduced depressive symptoms and
therefore possible antidepressant effects could come from using omega-3 fatty acids to treat bipolar
disorder. Similarly, Su et al. (2003) studied the effects of omega-3 polyunsaturated fatty acids in
patients with depressive disorder. The results showed a greater decrease on the Hamilton Rating
Scale for Depression (a qualitative survey to determine severity of depression) measured in patients
after they took the omega-3 pills than the patients who took placebo (olive oil) pills. This indicated
that the patients who took omega-3 pills showed less symptoms of depression.
One possible molecular pathway that can be studied to test if omega-3 fatty acids could be
used as a treatment for bipolar disorder is the biosynthetic pathway of inositol, which is used as part
of an important secondary messenger system in the brain (Levine 1997). In patients suffering
through the manic stage of bipolar disorder, a higher level of inositol than should be present is
found in the brain, while in the depressive stage, a lower level of inositol is present (Barkai et al.
1978). Lithium and VPA decrease inositol concentrations through inhibition of important steps in
inositol biosynthesis (Shaltiel et al. 2004). Lithium decreases inositol levels in the brain by inhibiting

several enzymes, which accounts for lithium’s benefits in treating the manic stage in bipolar disorder
(Hirvonen et al. 1991). Tokuoka et al. (2008) also found VPA to decrease inositol levels through
causing a defect in the signaling pathway of inositol. Similarly, Vaden et al. (2001) found a decrease in
inositol mass found in yeast cells when lithium and VPA were introduced.
On the contrary, in an ongoing unpublished study conducted by Dr. Marlene Murray,
omega-3 fatty acids seem to increase inositol levels in yeast cells (M. Murray, personal
communication); however, this is a preliminary study and the mechanisms behind how the omega-3
fatty acids increase inositol concentrations are unknown. Therefore, Dr. Murray’s lab uses yeast a
model system to understand the mechanism behind omega-3 fatty acid effects on inositol
production. The inositol production pathway in yeast is already known, and is one possible cellular
pathway that could explain the mechanism behind how omega-3 fatty acids influence inositol levels.
This pathway, which is similar in humans but more complex, is an important secondary messenger
system in the brain. Figure 1 shows the inositol production pathway, where glucose-6-phosphate is
converted into inositol-1-phosphate through the INO1 gene, and inositol-1-phosphate is then
converted into inositol through the INM1 gene. Vaden and colleagues found that valproate
decreased inositol levels in yeast cells while VPA increased expression of INO1, signifying a
feedback loop (2001). One explanation for this result could be that VPA seems to increase INO1
expression in order to produce more inositol-1-phosphate, and through this effect, produce more
inositol, that would make up for the decrease in inositol levels that it caused. However, while the
INO1 gene has been studied, not much research has been conducted on INM1. Thus, the aim of my
study is to test what effect the omega-3 fatty acid, docosahexaenoic acid (DHA), has on the
expression of the INM1 gene.

Fig. 1 The inositol production pathway in Saccharomyces cerevisiae which shows the genes INO1 and INM1 and their roles in producing
inositol.

Methods
In order to measure the expression of INM1, several general steps were taken. First, yeast
cultures were developed and cells grown in various media, followed by extraction of yeast cell
mRNA. Then, RT-qPCR was performed, and gene expression was calculated. A melt curve analysis
was then conducted to test for contamination and accuracy of data. Essentially, yeast cell DNA was
extracted, purified, and then amplified to see the differences between treatment (DHA) groups and
the control group.

Yeast Culture Development. In the first step, yeast cultures were developed in petri dishes
with growth media, which contain nutrients that support the development of yeast. The yeast cells
were then inoculated in various experimental conditions, as listed in the following: a control sample
without treatment, a positive control sample of yeast cells grown in a VPA solution, and three
experimental samples containing 0.2mM DHA, 0.4 mM DHA, and 0.6mM DHA treatments,
respectively. A positive control was used because the effects of VPA were already known and would

provide a comparison to the DHA treatment samples. Using various concentrations allowed for a
comparison of the INM1 gene expression quantity across dosages of DHA.
Spectrophotometry was then used to determine the cell density of the yeast grown in this
medium. This method determined the sample size of yeast (in mL) to be used for each sample by
measuring the quantity of yeast cells grown in the various treatments. After placing the measured
amount of yeast cells for each sample, they were allowed to grow overnight in a shaking incubator.
Spectrophotometry was performed again to determine yeast cell density in each sample after growth
in the incubator. This gave an indication of cellular density, so that the quantity of cell growth could
be measured for each of the variable and the control groups.

Extraction of mRNA. After the yeast cells were grown, the mRNA (messenger RNA) from
these cells were extracted. By measuring the cellular density of each test tube in the previous step,
the amount of mRNA extracted from the cells were measured, creating equal sample sizes of
mRNA. This allowed for the yeast mRNA counts to start at the same level in order to accurately
obtain the amount of INM-1 expressed later in the experiment. After obtaining the determined
volume of cells to be used, mRNA was extracted using the Bio-Rad spin protocol (Bio-Rad
instruction manual 2014). This procedure uses centrifugation as the main method of extraction.
Centrifugation separates cellular material based on their densities, so the yeast samples will separate
larger cellular matter like mRNA to the bottom of the sample tube in a solid cell pellet, while leaving
smaller materials in a liquid supernatant in the top layer. From the cell pellet, mRNA was extracted.

RT-qPCR. Following mRNA extraction, RT-qPCR was performed. This step can be
further divided into two steps of RT and qPCR. First, mRNA was converted into cDNA, and qPCR
was then performed to quantify gene expression levels.
Conversion to cDNA. The mRNA samples were converted to cDNA (complementary DNA)
using reverse transcriptase (RT), an enzyme that converts DNA into RNA. To quantify the amount

of cDNA converted from mRNA for each sample, the five samples were divided into halves. One
half of each sample was used as a control by not adding any RT. The second half of each sample
was used as the treatment sample by adding RT. The absence of RT would result in the inability for
mRNA to be converted into cDNA, allowing for a measurement of cDNA by comparing this
control sample to the RT-introduced sample. This resulted in a total of 10 samples, five controls
without RT and five treatments with RT. The samples are made up as follows:
•

Sample 1: control without RT

•

Sample 2: control with RT

•

Sample 3: VPA positive control without RT

•

Sample 4: VPA positive control with RT

•

Sample 5: 0.2mM DHA treatment sample without RT

•

Sample 6: 0.2mM DHA treatment sample with RT

•

Sample 7: 0.4mM DHA treatment sample without RT

•

Sample 8: 0.4mM DHA treatment sample with RT

•

Sample 9: 0.6mM DHA treatment sample without RT

•

Sample 10: 0.6mM DHA treatment sample with RT

These ten samples were placed in a 96-well plate and run through a thermal cycler, which converted
the mRNA of the solutions into cDNA by harnessing the RT enzyme. In heat, RT converts the
mRNA into cDNA. A final, rapid heating cycle denatures the RT enzyme so that it is not included in
the sample.
qPCR. The yeast cDNA was then put through a quantitative polymerase chain reaction,
which amplified the few cDNA strands obtained in the previous step into many strands of cDNA.
qPCR happens in two simplified steps. In this reaction, cDNA strands are denatured by heating,

meaning that the double-stranded DNA was split into two single strands. Then, an INM1 primer
that was introduced to the samples during cDNA conversion attaches only to the single DNA
strands that encode specifically for the INM1 gene. This results in the creation of two new DNA
molecules that carry the INM1 primer. Thus, with repeated cycles of this process, the cDNA strands
were multiplied exponentially, amplifying the cDNA molecules. During this amplification, a SYBR
green fluorescent marker specific to INM1 tags all of the DNA strands carrying the INM1 primer,
causing those DNA strands to fluoresce, and at the end of the cycles, the amount of fluorescence is
quantified to measure gene expression. RT-qPCR was also performed for the reference gene TFC1
in order to compare gene expressions.

Gene expression calculation. After RT-qPCR, gene expression was quantified through
relative quantification. This step compared of normalized the quantity of fluorescence of INM1 to
the quantify of fluorescence of TFC1. By normalizing INM1 expression to the reference gene with
known expression levels, INM1 expression was calculated through a comparison. The relative
quantification of INM1 expression was then normalized to the control with the absence of
treatment, where normalized expression ratio = 2-∆∆Ct.

Melt curve analysis. Following INM1 expression quantification, the reliability of the
expression data was observed through a melt curve analysis. As observed in figure 2, peaks around
75-80 degrees Celsius would have indicated contamination through primer dimers, which would be
due to two INM1 primers sticking together and causing SYBR green to tag it as a DNA strand
encoding for INM1. Figures 2 and 3 both show peaks around 80 degrees Celsius which is the
indicator INM1 expression, and figure 3 shows the ideal Melt peak graph indicating little to no
contamination.

Fig. 2 Melt curve analysis showing instances of contamination in gene expression, as observed in the peaks at approximately 78 degrees
Celsius. Data collected from previous trials not pertaining to the trials mentioned in this research.

Fig. 3 Melt curve analysis showing little to no contamination. A peak around 80 degrees Celsius indicates successful INM1 expression.

Results
As seen in figure 4, the data, averaged out of five trials, show positive INM1 expression for
all variable samples. Each variable group was normalized to the control group to observe the
increase or decrease in expression in the samples treated with either VPA or DHA dosages
compared to the control that did not contain treatment and therefore acted to produce the “normal”
amount of INM1 expression. Figure 5 shows the raw data of INM1 expression in each sample.
Cells treated with VPA showed highest INM1 expression, with INM1 expression increasing
with increasing DHA concentrations.
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Fig. 4 Average INM1 expression. Cells were grown for 24 hours in the variable concentrations indicated. Gene expression was measured by
RT-qPCR and normalized to non-treatment control. n = 5, VPA = positive control.

Trial 1

Trial 2

Trial 3

Trial 4

Trial 5

VPA

1.126

1.734

0.996

1.215

1.032

0.2 mM DHA

0.845

0.973

0.563

0.872

0.774

0.4 mM DHA

0.907

0.942

0.610

0.898

0.812

0.6 mM DHA

1.026

1.754

0.982

1.226

1.004

Fig. 5 Raw data of INM1 expression in each trial conducted for each variable sample. Values indicate gene expression normalized to nontreatment control.

Conclusion
The results show that VPA and the three DHA concentrations expressed more INM1
compared to the control group, as indicated by the positive values of expression seen in figures 4
and 5. A negative value would have indicated less INM1 expression in the variable group compared
to the control. Positive expression values in the VPA treated sample supports Vaden et al. and their
previous research where VPA was found to increase INO1 expression as well (2001).
Vaden and colleagues have found in previous experiments that INO1 expression is decreased
in the presence of DHA (2001); however, the data in this study show an increase in INM1
expression for the various DHA samples. This result shows indications for increased intracellular
inositol production in yeast cells treated with DHA, hinting that INM1 expression and INO1
expression might be influenced in different ways by omega-3 fatty acids. Furthermore, this finding
indicates that DHA does not work as a feedback loop as observed in the effects of VPA on inositol
production, but rather as a sort of transcription activator where INM1 activation results in increased
inositol production. However, further studies would need to be conducted in order to support this
hypothesis.
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